5,072 results on '"Filippatos, Gerasimos'
Search Results
2. Epidemiology and risk factors for hyperkalaemia in heart failure
3. Corticosteroid burst therapy in patients with acute heart failure: Design of the CORTAHF pilot study
4. Mineralocorticoid receptor overactivation: targeting systemic impact with non-steroidal mineralocorticoid receptor antagonists
5. Urinary Marker Profiles in Heart Failure with Reduced Versus Preserved Ejection Fraction
6. Finerenone and effects on mortality in chronic kidney disease and type 2 diabetes: a FIDELITY analysis.
7. Implications of worsening renal function before hospitalization for acute heart failure
8. Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR‐Preserved
9. Acute heart failure: diagnostic and prognostic assessment
10. New and emerging therapies in heart failure
11. Clinical trial design and interpretation
12. Titration of Medications After Acute Heart Failure Is Safe, Tolerated, and Effective Regardless of Risk
13. Characteristics, treatment, and outcomes of early vs. late enrollees of the STRONG-HF trial
14. Systemic oxidative stress associates with disease severity and outcome in patients with new-onset or worsening heart failure
15. Hospitalization for acute heart failure during non‐working hours impacts on long‐term mortality: the REPORT‐HF registry
16. DCRM 2.0: Multispecialty practice recommendations for the management of diabetes, cardiorenal, and metabolic diseases
17. Robustness of outcomes in trials evaluating sodium–glucose co‐transporter 2 inhibitors for heart failure
18. Performance of Different Risk Scores for the Detection of Atrial Fibrillation Among Patients With Cryptogenic Stroke
19. Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF Trial
20. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
21. Finerenone cardiovascular and kidney outcomes by age and sex: FIDELITY post hoc analysis of two phase 3, multicentre, double-blind trials
22. Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
23. CARDIOCARE platform: A beyond the state of the art approach for the management of elderly multimorbid patients with breast cancer therapy induced cardiac toxicity*.
24. CARDIOCARE: An integrated platform for the management of elderly multimorbid patients with breast cancer therapy induced cardiac toxicity.
25. Intravenous ferric carboxymaltose for iron repletion following acute heart failure in patients with and without diabetes: a subgroup analysis of the randomized AFFIRM-AHF trial
26. Differential biomarker expression in heart failure patients with and without mitral regurgitation: Insights from BIOSTAT-CHF
27. Implementation of a cardiogenic shock team in a tertiary academic center
28. Standardized Definitions for Evaluation of Acute Decompensated Heart Failure Therapies: HF-ARC Expert Panel Paper
29. Efficacy and Safety of Empagliflozin According to Background Diuretic Use in HFrEF: Post-Hoc Analysis of EMPEROR-Reduced
30. Left ventricular ejection fraction digit bias and reclassification of heart failure with mildly reduced vs reduced ejection fraction based on the 2021 definition and classification of heart failure
31. Non-steroidal mineralocorticoid receptor antagonists in heart failure
32. Multimorbidity in patients with acute heart failure across world regions and country income levels (REPORT-HF): a prospective, multicentre, global cohort study
33. Cardiorenal multimorbidity in hospitalized cardiology patients: The Hellenic Cardiorenal Morbidity Snapshot (HECMOS) study
34. Vascular Disease Burden, Outcomes and Benefits with Empagliflozin in Heart Failure: Insights From the EMPEROR-Reduced Trial
35. Atrial Fibrillation in Active Cancer
36. Discontinuation and non‐publication of heart failure randomized controlled trials: a call to publish all trial results
37. Implications of worsening renal function before hospitalization for acute heart failure
38. Adaptive versus conventional cardiac resynchronisation therapy in patients with heart failure (AdaptResponse): a global, prospective, randomised controlled trial
39. Global Variations According to Sex in Patients Hospitalized for Heart Failure in the REPORT-HF Registry
40. Management of Worsening Heart Failure With Reduced Ejection Fraction: JACC Focus Seminar 3/3
41. Abstract 15115: Efficacy and Safety of miR-132 Inhibitor CDR132L in Patients With Reduced Left Ventricular Ejection Fraction After Myocardial Infarction: Rationale for and Design of the HF-REVERT Trial
42. Abstract 12936: Quality of Life Assessments as Inclusion Criteria in Heart Failure Clinical Trials
43. Efficacy of empagliflozin in heart failure with preserved versus mid-range ejection fraction: a pre-specified analysis of EMPEROR-Preserved
44. The Han:SPRD Rat: A Preclinical Model of Polycystic Kidney Disease
45. FINERENONE IN CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES: A FIDELITY ANALYSIS OF LEFT VENTRICULAR HYPERTROPHY
46. Effect of SGLT2 Inhibitors on Cardiovascular Outcomes Across Various Patient Populations
47. Recency of Heart Failure Hospitalization, Outcomes, and the Effect of Empagliflozin: An EMPEROR-Pooled Analysis
48. Natriuretic Peptides: Role in the Diagnosis and Management of Heart Failure: A Scientific Statement From the Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America and Japanese Heart Failure Society
49. Minimal Clinically Important Differences in 6-Minute Walk Test in Patients With HFrEF and Iron Deficiency
50. Comparison of Investigator-Reported and Centrally Adjudicated Heart Failure Outcomes in the EMPEROR-Reduced Trial
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.